ArticleTherapeutic advances in musculoskeletal disease2009
Glucocorticoid-induced osteoporosis: treatment update and review.
Article in Therapeutic advances in musculoskeletal disease, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 63 citations in OpenAlex.
- Mechanisms of dexamethasone-induced bone toxicity in developing bone: a single-cell perspective.JBMR plus · 2025Article
- Clinical insights into the role of smoking, diabetes, and rheumatoid arthritis in osteoporotic fractures.Archives of osteoporosis · 2025Review
- Artifacts affecting dual-energy X-ray absorptiometry and bone mineral density measurements: a case report and review of the literature.Journal of medical case reports · 2025Review
- Epidemiology of Osteoporosis in Patients with Chronic Obstructive Pulmonary Disease in Taiwan.Journal of epidemiology and global health · 2024Article
- Mechanism of MiR-145a-3p/Runx2 pathway in dexamethasone impairment of MC3T3-E1 osteogenic capacity in mice.PloS one · 2024Article
- Article
- Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.British medical bulletin · 2022Article
- Androgen and glucocorticoid receptor direct distinct transcriptional programs by receptor-specific and shared DNA binding sites.Nucleic acids research · 2021Article
- When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis.Frontiers in endocrinology · 2021Review
- Unveiling the Metabolic Mystery of Fragility Hip Fracture in Indian Patients: A Histomorphometric and Biochemical Correlation.Indian journal of orthopaedics · 2020Article
- Transcriptome Analysis Reveals ThatBiology · 2020Article
- Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) - A primary prevention strategy.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Article
- Bilateral osteonecrosis of the hip in panhypopituitarism.BMJ case reports · 2019Article
- Hip fractures in the elderly without osteoporosis.Journal of frailty, sarcopenia and falls · 2018Article
- Factors influencing spinal sagittal balance, bone mineral density, and Oswestry Disability Index outcome measures in patients with rheumatoid arthritis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2018Article
- Vitamin DFrontiers in endocrinology · 2018Article
- Zoledronic acid in pediatric metabolic bone disorders.Translational pediatrics · 2017Review
- Icariin protects against glucocorticoid induced osteoporosis, increases the expression of the bone enhancer DEC1 and modulates the PI3K/Akt/GSK3β/β-catenin integrated signaling pathway.Biochemical pharmacology · 2017Article
- Long-term use of bisphosphonates in osteoporosis.Saudi medical journal · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoid-induced osteoporosis (GIO) is a serious consequence of glucocorticoid therapy leading to fractures in 30-50% of patients. A wide range of protective medications have been studied in this condition including calcium, vitamin D, vitamin D analogs, oral and intravenous bisphosphonates, sex hormones, anabolic agents and calcitonin. The mechanism of action, and evidence for these therapies, are reviewed - focusing on important trials and new evidence. Recently published guidelines are also reviewed and compared. Bisphosphonates are currently the recommended first-line therapy for the prevention and treatment of GIO. They have been shown to increase bone mineral density (BMD) at the spine and hip and to decrease the incidence of vertebral fractures (especially in postmenopausal women). Testosterone therapy and female hormone replacement therapy (HRT) have been found to increase lumbar spine BMD in hypogonadal patients on glucocorticoid therapy, but effects on hip BMD have not been consistent and there is no fracture data in the GIO population. Similarly, calcitonin increases lumbar spine BMD but has no proven fracture efficacy. The effect of selective estrogen receptor modulators, the oral contraceptive pill and strontium on GIO is relatively unknown. Parathyroid hormone (PTH 1-34) and zoledronic acid have emerged as exciting new options for the treatment of GIO. Both therapies have been found to result in gains in BMD at the spine and hip that are either noninferior or superior to those seen with oral bisphosphonate therapy. PTH 1-34 has also been found to decrease the incidence of new vertebral fractures and may be an option in high-risk patients established on long-term glucocorticoid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.